Abstract
Introduction
The impact of colonisation on the development of patent law continues to influence access to drugs and health care in developing countries including Nigeria. This flows from the mandatory provision of the Paris Convention which allowed the patent laws of the colonial masters to regulate the issue of patents in the various colonies. This consolidated the imposition of patent law on the colonies and enhanced the beneficial interest of the industrial nations to the detriment of the colonies including Nigeria. In this respect, Nigeria was pressured to adopt a patent law system at a time when there was a total absence of invention or industrial activity. In effect, the patent law system failed to spur inventions, innovations, research and development and the Nigerian societal growth remained "directionless." This resulted in inordinate policy articulation, formulation and implementation and exacerbates the public health care and related matters in a country endowed with enormous human and natural resources.
The contentions of this article asserts that the introduction of patent law in
Nigeria has neither delivered the benefits of the patent system, nor improved drug development, production or distribution to improve access to essential medicines. It is set out in three parts, the first part outlines the development of patent law and how colonization influenced the patent law development in Nigeria. In addition, this part reviews the use of colonial and national development plans to negate the development of an efficient patent law system, with its attendant impact on access to medicines and health care in Nigeria. It is argued that these development plans were meant to sustain the raw material base of the industries of the West without any genuine effort at technology transfer to the colonies. The effect of this has contributed to the inconsistency in patent and health care policies affecting the pharmaceutical sector in Nigeria. Part two analyses the pharmaceutical sector in Nigeria and other issues that impact on access to drugs and healthcare. The final part concludes the article.
Evolution of patent law
Patent law is the branch of intellectual property law that protects inventions in products and processes and gives the inventors the exclusive right to the use of the inventions for a limited period usually 20 years from the time of filing the applications. In this respect, patenting are allowed in ALMOST all fields of technology and incorporated in the laws of most countries. 1 The development of patent law evolved through the internationalisation with the formation of the Paris Union.
2 During this period, Britain annexed the colony of Lagos in 1861, the Protectorate of Northern Nigeria in 1900 and the Protectorate of Southern Nigeria in 1900 (together constituting the present day Nigeria). This followed the abolition of slave trade in 1807 3 and the expansion of trade in agriculture from Africa to Europe. 4 The legal system and administration introduced in Nigeria was that of the United Kingdom"s colonial authorities, which included the patent law ordinances and proclamations made applicable by the Foreign Jurisdiction Act 1845 and its subsequent amendments. 5 These have in no small way influenced patent law system in Nigeria. 6 The handing down of English patent laws was part of the standardized approach (or a template approach) of extension of administration to the colonies.
This standardized approach for patent law can be criticised both as unnecessary -as there were no inventions or industrial activities in Nigeria at the time of this extension -and also because these laws were carefully crafted to favour inventors and promote their inventions. By so favouring inventors, they favoured the industrialised Britain not Nigeria, a nation still focusing on peasant farming based on the use of rudimentary tools. Moreover, even at Nigeria independence, the imposition of foreign laws removed from the country the status of a sovereign and independent state which should "order its international and domestic affairs. the pressure from industrialized nations on developing and least-developed countries to join the "community of nations" in the Union; which was an attempt to view international patenting through the eyes of these countries.
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The administrative framework set up to implement the Convention followed In this respect, the Washington Conference, Article 16bis was adopted to regulate the application of the Convention to the colonies, possessions, and other subject territories (and this provision remained unchanged even after the Lisbon revision).
Article 16bis provides:
The Reflecting on the rationale for the enactment of patent legislation for the colonies, in the case of Ghana, the significant factor was the protection of the imperialist interest in the gold mining industry. Patent protection was provided for the machinery necessary for the exploitation of gold and other mineral resources. in sustaining the raw material base of the colonial masters.
These colonies and protectorates did not actively participate in the new formulation, nor were they taken into account when the international formulation was put in place. 34 Thus, while the participants at the conference were quick to accept that uniform legislation was "impossible in a world of national states with different interests, different legal structures and different economic histories, aspirations and ideologies." 35 Nevertheless, the movers of the Paris Convention were equally quick to bind the destinies, aspirations and ideologies of the colonial territories to their colonial masters, without their participation. 36 Thus the decision to enact a patent system for the colonies and protectorates did not consider the importance of such a system to the socio-economic situation in these colonies.
The imposition of European institutions, norms, and systems -including the patent system -on the cultural, economic, and legal landscape, was an expansion of the colonial enterprise, 37 than the exception. However, the health sector has not leveraged on the existing patent system, and health condition of the population is an indication of ineffective patent system in the country. 58 This is made obvious by the incidence of HIV/AIDS, malaria pandemic, tuberculosis and other communicable diseases. 59 There is need to tackle the health problems through a patent system that will enhance access to essential life saving medicines. Certainly the need to reposition the patent law system would enhance the vibrancy of the pharmaceutical sector.
The Pharmaceutical Industry Issues
The colonial impact on the Nigerian pharmaceutical sector can be observed in the five stages in its evolution. The first phase, the pre 1957 era dominated by foreign multinationals involved in the business of distribution of imported drugs, there was no local participation in the drug business. 60 This goes to support the fact that inventions and patenting was entirely a foreign business that was alien to the colonies. An additional redress by the government have involved some policy documents which include the "Vision 2010 report;" 73 the "National Economic Empowerment and Development Strategy (NEEDS)," which was expected to lapse in 2013, and the "Visioning for 2020" with ITS 7-points agenda. 74 Though these documents have been abandoned by the government, it is observable that none of these documents mentioned the need for the Patents and Designs Act or any patent legislation for that matter. This in fact makes it evident that every "government in power" sets out its own agenda and discards any existing agenda. The editorial comment of the Guardian has identified these development agendas as constraints to national development. 75 The reality of the change in policy objectives is that the government hides behind the policy framework as a smoke screen with every succeeding government in Nigeria creating an obstacle with their policy framework.
This affects most development, policy and administrative issues, including the patent law system and administration, an inconsistency that has become a colonial hangover trailing Nigeria.
In the context of inventions and patenting, patent rights have enormous public health implications for access to drugs and healthcare. These include the neglect in researching and developing drugs for diseases prevalent in developing countries, making the price of existing drugs unaffordable and strengthening pharmaceutical policies and practices that would discourage innovation and domestic generic industries. The neglect has exacerbated the health conditions and is currently manifesting as crisis in healthcare of developing countries, with 95% of the global total, of people living with HIV, actually live in developing world. 76 As the patent system and administration has not received attention in Nigeria and the lack of an effective law on the production of essential drugs or the generic versions of the drugs. The imposition of laws has not laid the foundation for Nigeria pharmaceutical sector to grow and improve upon and this has resulted to inconsistency in policy articulation, formulation and implementation within the health sector. The implication is that the health sector is neglected and this affects access to drugs, high cost of drugs, and poor infrastructural development leading to the prevalence of fake, substandard and counterfeit drugs as the order of the day. development plans, a weak system that could not tap on the gains of a patent system nor institute a workable patent system. This weak foundation has impacted on the emergent independent Nigeria resulting in instability, and inconsistency in policy articulation, formulation and implementation.
The cumulative effect of the historical development manifests the protection of the colonial master"s interest in the development of the raw material base on one hand and the protection of their investments and potential investments on the other.
This diminished the objective for introducing the patent law system for the promotion of inventions even at the rudimentary level for the colonies. Rather, it enthroned an administrative structure that will secure the raw material base for the industries of the colonial masters. This affected the emergent independent governance structure to align with the thinking of "any government in power." The effect of the above is that the patent law system and administration did not receive any attention and there was no effort at using the system to enhance research and development, invention, innovation or even technology transfer for the pharmaceutical sector to enhance access to drugs and health care in Nigeria. has been found for an existing compound. The Nigerian legislature should use the available policy space and freedom to limit the grant of patents for new uses of known compounds which in effect extend the life of a patent beyond 20 years.
Secondly, the expectation is that generic companies must replicate the full set of test data necessary to obtain approval even where a product is off-patent. Their inability to gain marketing approvals based on the clinical data places the cost burden on production which will be passed on to the consumer. Therefore, the provisions of the US FTAs mandating the regulatory agencies to refuse marketing approval to generic versions of products if a patent thereon is in force except with the consent of the patent owner. This puts the responsibility of patent protection on the regulatory agencies and relieves the courts from their judicial responsibility of determining the rights of the patent owner. Therefore, a regulatory agency like NAFDAC, involved in the safety and marketing standards, would get involved in the validity of patents through registration, which is beyond the statutory mandate that set up this regulatory agency. The reform agenda would be an opportunity to resolve the issue of protection of undisclosed information relating to data exclusivity which would allow the generic manufacturers" access to data needed for neglected diseases specific to Nigeria. In addition, this would streamline the functions of NAFDAC and the Nigerian patent office in the determination of a patent life.
Thirdly, the exceptions to patent rights provided by the TRIPS Agreement allows for additional policy options for developing and least developed countries to make drugs accessible and affordable. These are measures meant to ensure transfer of technology, dissemination of knowledge and to circumvent anti-competitive actions of the research based pharmaceutical companies. Such measures include compulsory licensing, government use exceptions and parallel importation. These flexibilities are available for member states to resort to and could mitigate the negative impacts of the patent system and sustain the advantages of the system. However, the need for them to gain legislative efficacy is required and this can only be achieved through legislative reform, judicial efficiency, resolution and strengthening of institutional and administrative issues hindering access to health care. In this respect therefore, the newly elected legislature needs to treat the NIPCOM Bill as a priority issue in the legislative agenda for the interest of public health care.
In addition, it is recommended that the Nigerian Government should address the issues of health budgeting, budget implementation, manpower development and above all sustain the fight against corruption. These are Non-TRIPS options which should be reviewed and strengthened for a long term policy plan implementation that enjoys cross-party support independent of changes in Government. Attention must also be given to institutional development, infrastructural development, drug production, procurement, storage and manpower development in Nigeria. Though there has been much rhetoric surrounding the war against corruption in Nigeria, this war should not be used to satisfy the political egos of those in power. Rather it should be sustained to enhance project formulation and implementation so as to achieve efficacy, improve and sustain enhance access to drugs and healthcare in Nigeria.
